Thus, future therapeutic assays involving immunomodulation as a first line treatment will reasonably be targeted first to patients with an autoantibody-mediated severe ADAMTS13 deficiency. This evidence concerns the gene ADAMTS13 and hyperinsulinemic hypoglycemia, familial, 4.